Infectious complications in children with acute myeloid leukemia: Decreased mortality in multicenter trial AML-BFM 2004

Blood Cancer Journal

Volumn 6, Issue 1, 2016, Pages

  Bochennek, K ^a   Hassler, A ^a   Perner, C ^a   Gilfert, J ^a   Schoning S ^a   Klingebiel, T ^a   Reinhardt, D ^b   Creutzig, U ^c   Lehrnbecher, T ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; COMPLICATION; FEMALE; HUMAN; INCIDENCE; INFANT; INFECTION; LEUKEMIA, MYELOID, ACUTE; MALE; MORTALITY; MULTICENTER STUDY; NEWBORN; PRESCHOOL CHILD; SEPSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFECTION; LEUKEMIA, MYELOID, ACUTE; MALE; SEPSIS;

EID: 84986293301     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.110     Document Type: Article

References (20)

1. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18:72-77.
2. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007;110:3532-3539.
3. Lehrnbecher T, Foster C, Vazquez N, Mackall CL, Chanock SJ. Therapy-induced alterations in host defense in children receiving chemotherapy. J Ped Hematol Oncol 1997;19:399-417.
4. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120:3187-3205.
5. Santolaya ME, Rabagliati R, Bidart T, Paya E, Guzman AM, Morales R et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol 2005;22:S79-S113.
6. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82:S105-S117.
7. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-1238.
8. Lehrnbecher T, Sung L. Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia. Expert Rev Hematol 2014;7:819-830.
9. Nolt D, Lindemulder S, Meyrowitz J, Chang BH, Malempati S, Thomas G et al. Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML). Pediatr Blood Cancer 2015;62:1149-1154.
10. Kurt B, Flynn P, Shenep JL, Pounds S, Lensing S, Ribeiro RC et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 2008;113:376-382.
11. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 2013;122:37-43.
12. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-1110.
13. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
14. Castagnola E, Rossi MR, Cesaro S, Livadiotti S, Giacchino M, Zanazzo G et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer 2010;55:1103-1107.
15. Lewis V, Yanofsky R, Mitchell D, Dix D, Ethier MC, Gillmeister B et al. Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group. Pediatr Infect Dis J 2014;33:126-129.
16. Felsenstein S, Orgel E, Rushing T, Fu C, Hoffman JA. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia. Pediatr Infect Dis J 2015;34:e78-e84.
17. Lehrnbecher T, Ethier MC, Zaoutis T, Creutzig U, Gamis A, Reinhardt D et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol 2009;147:125-128.
18. Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014;15:e327-e340.
19. Molgaard-Hansen L, Mottonen M, Glosli H, Jonmundsson GK, Abrahamsson J, Hasle H et al. Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. Br J Haematol 2010;151:447-459.
20. Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 1999;106:436-444.